Nov 17, 2024, 09:07 | Blog

Sumanta K. Pal: Always learning something new from Tom Powles

Sumanta K. Pal, Medical Oncologist at the City of Hope Comprehensive Cancer Center, shared a…

Nov 8, 2024, 18:55 | Insight

Regina Barragan-Carrillo: First and second - line treatments in metastatic renal cell carcinoma

Regina Barragan-Carrillo, Postdoctoral fellow at the Genitourinary Clinic at the Medical Oncology and Medical Therapeutics…

Nov 8, 2024, 13:58 | Blog

Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials

Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent…

Nov 6, 2024, 12:05 | Blog

Karl Semaan: Landscape of subsequent therapies in perioperative immunotherapy trials

Karl Semaan, Postdoctoral Oncology Research Fellow at Dana-Farber Cancer Institute, posted on X about recent…

Nov 5, 2024, 17:40 | Blog

Tom Powles: First-Line UC Trials - Ipi/Nivo Fails on OS, Durva/Treme Shows Potential in PD-L1 Positive Patients

Tom Powles, Director of Barts Cancer Centre, shared a post on X: "Just out. Ipi/nivo…

Nov 5, 2024, 01:12 | Blog

Shilpa Gupta: NIAGARA trial insights on bladder cancer treatment

Shilpa Gupta shared a post by UroToday on X, adding the following: “Had a great…

Nov 3, 2024, 12:59 | Insight

Uromigos Live24 panel on novel ADCs in urothelial carcinoma

Uromigos shared a post on X: “Don't get spooked by new data - watch the…

Oct 28, 2024, 09:59 | Blog

Tom Powles: Phase 1b data with the HIF2a inhibitor casdatifan in clear cell patients

Tom Powles, Director of Barts Cancer Centre, shared a post on X: "Phase 1b data…

Oct 19, 2024, 16:37 | Drugs

Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S. market

Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it…

Oct 18, 2024, 19:24 | Blog

Bladder preservation in muscle-invasive bladder cancer - 57th Urology Course

57th Urology Course posted on LinkedIn: "Debate: Bladder preservation in muscle-invasive bladder cancer. Bladder preservation…

Oct 13, 2024, 10:59 | Insight

Alessandro Di Federico: Honored to have our work highlighted in this months issue of Annals of Oncology

Alessandro Di Federico shared a post by Annals of Oncology on X, adding: "Honored to have…

Oct 10, 2024, 18:35 | Blog

Chandler Park: Enjoyed reviewing the data from the top GU oncologists from around the world at Uromigos Live 24

Chandler Park posted the following on LinkedIn: “Thank you Brian Rini, Tom Powles, The Uromigos…

Oct 10, 2024, 14:16 | Dialogues

NIAGARA Study Insights: Durvalumab and Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas

In this episode of OncoDaily, Dr. Petros Grivas joins host Chandler Park to discuss the…

Oct 5, 2024, 23:32 | Insight

AstraZeneca Revealed Positive Results for Muscle Invasive Bladder Cancer Patients at ESMO 2024

IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of…

Oct 4, 2024, 08:17 | Blog

Zainab Shinkafi-Bagudu: There is power in numbers

Zainab Shinkafi-Bagudu shared a post on LinkedIn by Creation.co adding: "The power and reach of…

Sep 30, 2024, 16:54 | Insight

Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer

Tom Powles shared an article on X: "Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder…

Sep 24, 2024, 11:31 | Blog

Tom Powles: How does Sunniforcast data fit into the non-clear cell landscape

Tom Powles shared a post on X: ''How does Sunniforcast data fit into the non-clear…

Sep 21, 2024, 14:04 | Blog

Enrique Grande: Another practice changing trial in the back

Enrique Grande shared a post on X: ''NIAGARA is the first randomized trial to demonstrate…

Sep 20, 2024, 12:57 | Blog

Neeraj Agarwal: The 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +/- durvalumab in MIBC

Neeraj Agarwal shared a post on X: "Breaking news (practice changing) from ESMO24, Tom Powles…

Sep 20, 2024, 12:55 | Insight

Tom Powles: The 1st disitimab Vedotin and pembro in HER 1-3 urothelial carcinomas

Tom Powles shared a post on X: "The 1st disitimab Vedotin (HER-2 MMAE ADC) and…

Sep 19, 2024, 15:48 | Insight

Tom Powles: The 1st perioperative immune therapy study to show an OS in bladder cancer

Tom Powles shared a post on X: “Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder…

Sep 19, 2024, 04:32 | Societies

Best of ESMO24

The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…

Sep 17, 2024, 16:42 | Blog

Tom Powles: SUNNIFORCAST at ESMO24

Tom Powles shared a post on X: "SUNNIFORCAST at ESMO24 ipi/nivo vs VEGF based therapy…

Sep 17, 2024, 10:06 | Insight

Sumanta K. Pal: Important analysis of SWOG 1500 published just ahead of ESMO24

Sumanta K. Pal shared a post on X: "Huge congrats to Pedro C Barata, who drove…

Sep 16, 2024, 16:31 | Societies

40 Posts Not To Miss From ESMO24 Day 3

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…

Sep 16, 2024, 16:18 | Societies

Key Findings from the NIAGARA Trial at ESMO 2024

The results of the NIAGARA trial were recently presented at ESMO 2024. The NIAGARA trial,…

Sep 15, 2024, 12:53 | Blog

Sumanta Pal's highlights from ESMO24

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…

Sep 14, 2024, 17:15 | Societies

45 Posts not to miss from ESMO24 Day 1

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…

Sep 14, 2024, 15:38 | Insight

ESMO24 Day 1 highlights by Tom Powles

The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona. ESMO24…

Sep 10, 2024, 14:54 | Blog

Tom Powles: Belzutifan for clear cell renal cancer

Tom Powles shared a post on X: “Belzutifan significantly outperformed Everolimus in heavily pretreated clear…

Sep 10, 2024, 05:00 | Blog

Tian Zhang: Lots of bladder cancer data coming at ESMO24

Tian Zhang shared a post on X by Tom Powles adding: "Lots of bladder cancer…

Sep 9, 2024, 14:16 | Blog

Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions

Tom Powles shared a post on X, about recent paper published in ESMO Open: The…

Aug 27, 2024, 19:10 | Blog

Petros Grivas: Looking forward to a fantastic ESMO24

Petros Grivas shared a post on X by ESMO, adding: "Looking forward to a fantastic…

Aug 26, 2024, 21:30 | Blog

Tian Zhang: 3 weeks til ESMO24!

Tian Zhang shared a post by ESMO on X, adding the following: “T -3 weeks…

Aug 26, 2024, 20:08 | Insight

Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer

Tom Powles, Professor of urology cancer at the University of London and the Director of…

Aug 14, 2024, 12:07 | Blog

Oncoinfluencers to Follow on Social Media: Dr. Tom Powles

We are excited to spotlight Dr. Tom Powles, a leading expert in urological oncology, as…

Aug 6, 2024, 03:43 | Blog

Tian Zhang: CtDNA to replace radiology for disease recurrence?

Tian Zhang posted on X: "Fiery discussion on minimal residual disease for bladder cancer —…

Aug 4, 2024, 17:13 | Insight

Shilpa Gupta: Community oncologists discuss the real world practice patterns in GU cancers at WorldGU24

Shilpa Gupta shared on X: “WorldGU24, An amazing session with The Uromigos, Tom Powles, Brian Rini…

Aug 4, 2024, 14:30 | Societies

8 Posts Not To Miss From GUWorld24!

The 2024 World Conference On Genitourinary Cancers (GUWorld24) took place from August 1st to 3rd…

Jul 30, 2024, 12:56 | Blog

Tian Zhang: Uromigos anticipating some lively discussions

Tian Zhang shared a post by Uromigos on X, adding: "See you next week at World GU,…

Jul 28, 2024, 13:01 | Insight

Brian Rini: Excited for our session with WorldGU24

Brian Rini, Chief of Clinical Trials at Vanderbilt University, shared a post by Uromigos on…

Jul 28, 2024, 08:32 | Blog

At ANZUP 24 Cristiane Bergerot presented a new HRQOL measure for patients with localized and metastatic RCC - Florez Lab

Florez Lab shared on X: "At ANZUP 24 Dr. Cristiane Bergerot presented a new HRQOL…

Jul 21, 2024, 09:13 | Insight

Sumanta K. Pal: Excellent review on kidney cancer from Tom Powles

Sumanta K. Pal shared on X a recent paper by Matthew Young et al. titled…

Jul 20, 2024, 18:07 | Blog

Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer

Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…

Jul 14, 2024, 21:15 | Blog

Sumanta K. Pal: Excellent use of Twitter polls to reconcile tough clinical scenarios

Sumanta K. Pal shared a post on X: ''Brilliant insights from Tom Powles, Barts Cancer Institute.…

Jul 14, 2024, 05:39 | Blog

Thomas Powles: An intratumoral micro-device releases small amounts of drugs locally to assess efficacy

Thomas Powles posted on X: "An intratumoral micro-device releases small amounts of drugs locally to…

Jul 13, 2024, 12:22 | Insight

Key Highlights from KCRS24 by Sumanta K. Pal

Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in Boston focused…

Jul 12, 2024, 13:32 | Societies

Insights from KCRS24 by Neeraj Agarwal

Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in…

Jul 10, 2024, 11:57 | Blog

The 2024 Uromigos Cup

Uromigos formed in early 2017 as a group of friends attempting to provide balanced, scientific content…

Jul 7, 2024, 14:06 | Blog

Christian Gratzke: Great to have Tom Powles at Uro Trials

Christian Gratzke, Urologic Surgeon and Chair at University of Freiburg, shared on X: "Great to have…

Jul 7, 2024, 04:49 | Insight

Harold J. Burstein: Important questions about 'getting to 2nd line therapy.'

Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared a…

Jul 6, 2024, 13:29 | Blog

ESMO - immune cell-related biomarkers in metastatic HNSCC

ESMO shared on LinkedIn: "Latest podcast. Annals of Oncology Editor in Chief Tom Powles talks to…

Jul 6, 2024, 08:45 | Insight

Tom Powles on RCC patients receiving ICI therapy

Tom Powles shared on X: “During the period of PD-1 inhibition availability for RCC in…

Jul 5, 2024, 05:41 | Blog

Abeid Athman: Joining ASCO had a huge role in shaping my career

Abeid Athman, Clinical Oncologist at Kenyatta University Hospital, shared on X: "It has been 5…

Jul 2, 2024, 11:12 | Blog

Enrique Grande: Fabulous and inspiring view of the short term future of advanced bladder cancer

Enrique Grande shared a post on X: …

Jul 1, 2024, 14:48 | Blog

Daniel Castellano: Great proposals in a urothelial cancer workshop at GUARD Symposium 2024

Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: “Great discussion and…

Jul 1, 2024, 01:24 | Blog

Daniel Castellano: Biomarker selected bladder sparing preservation program is the future

Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: "Excellent and clarifier…

Jun 26, 2024, 13:51 | Insight

Tom Powles: Durvalumab with neoadjuvant chemo then cystectomy in MIBC

Tom Powles shared on X: "Positive results from the NIAGARA Phase III trial showed durvalumab…

Jun 26, 2024, 03:43 | Blog

Roberto Iacovelli: Honour to have TIDE-A commented by Laurence Albiges, Tom Powles and Dr. Wells

Roberto Iacovelli shared a post on X: "Great honor to have TIDE-A commented by Laurence…

Jun 20, 2024, 05:06 | Blog

Pedro C Barata: Check out the wonderful editorial led by Jason Brown

Jason Brown, GU Oncologist at University Hospitals, shared a post by Pedro C Barata, GU Med Oncologist…

Jun 15, 2024, 07:36 | Blog

Tom Powles and Giorgio Bogani Discuss the Recently Published Study on Advanced or Recurrent Endometrical Cancer

The European Society for Medical Oncology (ESMO) posted on LinkedIn: “Latest podcast Annals of Oncology Editor-in-Chief…

Jun 6, 2024, 10:02 | Societies

Tom Powles: Great investigator-initiated study from LACOG and Fernando Maluf

Tom Powles, Director of Barts Cancer Center, shared a post on X: "40% response rate…

Jun 5, 2024, 12:44 | Blog

Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24

Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: ''Perhaps the most important long-term…

Jun 1, 2024, 12:50 | Blog

Lennard YW Lee: We are now one of the leading cancer research infrastructure for personalised cancer vaccine trials

Lennard YW Lee, Associate Professor at the University of Oxford, shared on LinkedIn: "Feeling proud…

Jun 1, 2024, 10:00 | Insight

Tom Powles: TROPICS-4 in heavily pretreated bladder cancer missed OS

Tom Powles, Director of Barts Cancer Center, shared on X: “TROPICS-4 (sacituzumab, govitecan versus chemo) in…

May 28, 2024, 14:33 | Societies

Tom Powles: Final results for axitinib/avelumab in 1st line RCC at ASCO24

Tom Powles, Director of Barts Cancer Center, shared on X: "Final results for axitinib/avelumab in 1st…

May 28, 2024, 07:49 | Insight

Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out

Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…

May 27, 2024, 05:34 | Opinion

Tom Powles: The ASCO 24 highlight In My Opinion

Tom Powles, Director of Barts Cancer Center, shared on X: “The ASCO 24 highlight IMO. Currently…

May 26, 2024, 11:35 | Insight

Bladder cancer highlights for ASCO24 by Tom Powles

Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "Bladder cancer highlights for ASCO24. Practice…

May 26, 2024, 11:15 | Insight

Tom Powles: 3 renal cancer biomarker orals at ASCO24

Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "3 renal cancer biomarker orals at…

May 24, 2024, 00:08 | Blog

Tom Powles: Mixing papillary and other ‘non-clear cell’ renal cancers guidlines has hampered new treatments

Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "The ESMO guidlines make a clear…

May 23, 2024, 13:33 | Insight

Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing

Tom Powles, Director of Barts Cancer Center, shared a post on X: "Neoadjuvant chemo/nivolumab with…

May 23, 2024, 13:04 | Blog

Tom Powles on the NADINA trial

Tom Powles, Director of Barts Cancer Center, shared a post on X: "The NADINA trial…

May 23, 2024, 07:58 | Insight

Tom Powles on new ESMO guidelines for renal cancer

Tom Powles, Director of Barts Cancer Center, shared on X: "New ESMO guidelines in advanced papillary…

May 18, 2024, 11:30 | Insight

Tom Powles: Annual meeting of the CARE 1 metastatic 1st line RCC study

Tom Powles, Director of Barts Cancer Center, shared a post on X: “Annual meeting of…

May 12, 2024, 14:34 | Societies

Tom Powles talks to Amanda Psyrri about immune cell-related biomarkers in HNSCC - ESMO

ESMO - European Society for Medical Oncology shared on LinkedIn: “Latest podcast Annals of Oncology…

May 12, 2024, 13:37 | Blog

Two Onc Docs: Tom Powles and Brian Rini discuss metastatic RCC

Two Onc Docs shared a post on X: "We are back this week with Tom Powles…

May 7, 2024, 10:25 | Career

Tom Powles has been named in TIME100 Health - Barts and The London School of Medicine and Dentistry

Toni Choueiri shared a post by Barts and The London School of Medicine and Dentistry…

Apr 20, 2024, 20:30 | Insight

Tom Powles: Adjuvant pembrolizumab in clear cell renal cancer for the 1st time (KN564)

Tom Powles, Director of Barts Cancer Center, recently shared on X: "Adjuvant pembrolizumab shows a…

Apr 20, 2024, 06:03 | Insight

Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!

Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…

Apr 16, 2024, 01:39 | Drugs

Tom Powles reflects on conducting less successful trials in Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X: "We have not had…

Apr 11, 2024, 08:13 | Drugs

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…

Apr 8, 2024, 15:41 | Drugs

Tom Powles: This seems an ambitious accelerated approval in UC

Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…

Apr 1, 2024, 19:03 | Blog

Top Influencers in GU Ocology by LARVOL

LARVOL shared on their X/Twitter page: "Delving into GU Oncology, we’re thrilled to spotlight the…

Apr 1, 2024, 15:31 | Blog

Tom Powles: Easter paper of the month with Matt Galsky

Tom Powles, Director of Barts Cancer Center, shared a post on X: "Easter paper of…

Mar 17, 2024, 19:51 | Insight

Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care

Tom Powles, Director of Barts Cancer Center, shared a post on X: "New ESMO's guidelines for…

Mar 15, 2024, 15:26 | Insight

Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki

Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…

Feb 5, 2024, 15:59 | Blog

Tom Powles: Summary of clinical trials in advanced non-clear cell RCC GU24

Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: “Summary of clinical…

Feb 1, 2024, 17:14 | Insight

Sumanta K. Pal: She has developed what I think should be called the 'Bergerot QOL Index ' for kidney cancer

Sumanta K. Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared…

Dec 23, 2023, 03:46 | Blog

Barts Health NHS Trust: Tom Powles features in Nature’s 10

Barts Health NHS Trust shared on LinkedIn: “A Barts Health doctor whose research has helped…

Dec 19, 2023, 09:13 | Blog

Yüksel Ürün: Congratulations to Tom Powles for being recognized as one of the top influencers in science for the year 2023 by Nature!

Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently…

Dec 19, 2023, 09:10 | Insight

Tom Powles: EV/pembro will transform the lives of many patients with this difficult disease

Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "A big day…

Dec 4, 2023, 15:11 | Blog

Tom Powles: This is the next chapter IMO

Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "Treatment for muscle…

Nov 9, 2023, 18:28 | Blog

Chandler Park: Fun GU oncology weekend

Chandler Park, Voting member of the American Society of Clinical Oncology (ASCO) State Council, recently…

Nov 1, 2023, 18:54 | Societies

20 Posts Not To Miss From ESMO 2023 Congress

The Annual Congress of the European Society For Medical Oncology (ESMO) took place from October…

Oct 26, 2023, 16:27 | Blog

Benjamin Auberger: This major study naturally raises several questions

Quoting Benjamin Auberger, Oncologist at CHRU Brest, on LinkedIn: "A wow presidential session with a…

Oct 25, 2023, 17:27 | Insight

Tom Powles: TAR-210 releases Erdafitinib slowly into the bladder by a novel release system

Tom Powles, Director of Barts Cancer Centre, shared on Twitter: ''Something NEW. TAR-210 releases Erdafitinib…

Oct 23, 2023, 15:26 | Insight

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…

Oct 21, 2023, 14:04 | Drugs

Tom Powles: Renal cancer highlights ESMO23

Tom Powles Director of Barts Cancer Centre, shared a post on LinkedIn, saying: "Renal cancer…

Oct 14, 2023, 16:32 | Insight

Daniel Chen: After a decade of immense progress for patients with cancer immunotherapy we are excited to publish a 10-year update, reflecting the complexity in the TME.

Daniel Chen, Founder of Engenuity Life Sciences, shared on LinkedIn: "We wrote the Cancer Immunity Cycle…